Modalis Therapeutics Advances CRISPR-GNDM Technology for Rare Diseases

TOKYO, Jul 14 (Pulse News Wire) – Modalis Therapeutics Corporation (4883.T) disclosed plans to advance its CRISPR-GNDM technology aimed at treating rare diseases. The company highlighted the non-cutting approach of its CRISPR-GNDM®, which offers sustained therapeutic effects through a single administration without repeated dosing.

Clinical trials for MDL-101, targeting LAMA2-RD, showed significant improvements in weight, grip strength, survival rates, and health scores in mouse models. Modalis is making progress toward clinical development with key milestones planned for late 2026 to early 2027.

The company's hybrid business model combines collaborative and internal pipeline strategies, focusing on securing funding and partnerships to ensure successful clinical entry and long-term value creation. With a capital of ¥885 million and 21 employees, Modalis continues to develop its innovative gene editing solutions while managing risks associated with intellectual property, revenue stability, and talent acquisition.